This site does not support your browser.
We recommend you to upgrade to the latest version:
EFFICACY AND SAFETY OF LURBINECTEDIN (PM1183, ZEPSYRE®) IN SMALL CELL LUNG CANCER (SCLC): RESULTS FROM A PHASE 2 STUDY
LURBINECTEDIN (PM01183) WITH DOXORUBICIN (DOX), AN ACTIVE TREATMENT AS SECOND-LINE THERAPY IN SMALL CELL LUNG CANCER (SCLC)
Foster M ASCO 2015
OVERALL SURVIVAL WITH LURBINECTEDIN PLUS DOXORUBICIN IN RELAPSED SCLC. RESULTS FROM AN EXPANSION COHORT OF A PHASE Ib TRIAL
IASLC. Toronto, 2018
ACTIVITY OF LURBINECTEDIN AS SINGLE AGENT AND IN COMBINATION IN PATIENTS WITH ADVANCED SMALL CELL LUNG CANCER (SCLC)
ACTIVITY AND SAFETY OF THE COMBINATION OF LURBINECTEDIN (PM1183) AND DOXORUBICIN IN RELAPSED SCLC. FINAL RESULTS OF A PHASE LB TRIAL
IASLC Yokohama – Japan 2017
Our strong commitment to oncology translational research along with our deep understanding of the marine biodiversity of our oceans is placing us at the head of marine biotechnology.
If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom